Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Kline, Christopher ^a   Ndjomou, Jean ^a   Franks, Tamera ^a   Kiser, Rebecca ^b   Coalter, Vicky ^b   Smedley, Jeremy ^b   Piatak Jr , Michael ^b   Mellors, John W ^a   D Lifson, Jeffrey ^b   Ambrose, Zandrea ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DOSE INTENSIFICATION; GASTROINTESTINAL TRACT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; LYMPH NODE; LYMPHOID TISSUE; MACACA NEMESTRINA; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TISSUE LEVEL; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTI-RETROVIRAL AGENTS; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HIV REVERSE TRANSCRIPTASE; KINETICS; LEUKOCYTES, MONONUCLEAR; MACACA; MALE; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84893168475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084275     Document Type: Article

References (62)

1. Chun TW, Davey RT Jr., Engel D, Lane HC, Fauci AS (1999) Reemergence of HIV after stopping therapy. Nature 401: 874-875. doi: 10.1038/44755. PubMed: 10553903.
2. García F, Plana M, Vidal C, Cruceta A, O'Brien WA et al. (1999) Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13: F79-F86. doi: 10.1097/00002030- 199907300-00002. PubMed: 10449278. (Pubitemid 29408440)
3. Harrigan PR, Whaley M, Montaner JS (1999) Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13: F59-F62. doi: 10.1097/00002030- 199905280-00001. PubMed: 10371167. (Pubitemid 29240180)
4. Neumann AU, Tubiana R, Calvez V, Robert C, Li TS et al. (1999) HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 13: 677-683. doi:10.1097/00002030-199904160-00008. PubMed: 10397562. (Pubitemid 29286702)
5. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295. doi:10.1126/science.278.5341.1291. PubMed: 9360926. (Pubitemid 27495741)
6. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M et al. (2012) Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLOS ONE 7: e33948. doi:10.1371/journal.pone.0033948. PubMed: 22479485.
7. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195: 1762-1764. doi:10.1086/518250. PubMed: 17492591. (Pubitemid 46870248)
8. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I et al. (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9: e1003211. PubMed: 23516360.
9. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410-1418. doi:10.1086/428777. PubMed: 15809898. (Pubitemid 40563351)
10. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16: 460-465. doi:10.1038/nm.2111. PubMed: 20228817.
11. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D et al. (2003) Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77: 11212-11219. doi:10.1128/JVI.77.20.11212-11219.2003. PubMed: 14512569. (Pubitemid 37204311)
12. Ramratnam B, Ribeiro R, He T, Chung C, Simon V et al. (2004) Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 35: 33-37. doi: 10.1097/00126334- 200401010-00004. PubMed: 14707789. (Pubitemid 38044779)
13. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ et al. (2005) Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79: 9625-9634. doi:10.1128/JVI.79.15.9625-9634.2005. PubMed: 16014925. (Pubitemid 41022306)
14. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H et al. (2010) Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS, 24: 2451-60. PubMed: 20827162.
15. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80: 6441-6457. doi:10.1128/JVI. 00591-06. PubMed: 16775332. (Pubitemid 43927447)
16. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW et al. (2004) Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189: 1452-1465. doi: 10.1086/382488. PubMed: 15073683. (Pubitemid 38543595)
17. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3: e46. doi:10.1371/journal.ppat.0030046. PubMed: 17411338.
18. Nottet HS, van Dijk SJ, Fanoy EB, Goedegebuure IW, de Jong D et al. (2009) HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 50: 345-353. doi: 10.1097/QAI.0b013e318197eb04. PubMed: 19214126.
19. Persaud D, Ray SC, Kajdas J, Ahonkhai A, Siberry GK et al. (2007) Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 23: 381-390. doi:10.1089/aid.2006.0175. PubMed: 17411371. (Pubitemid 46608558)
20. Balzarini J, Weeger M, Camarasa MJ, De Clercq E, Uberla K (1995) Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun 211: 850-856. doi:10.1006/bbrc.1995.1890. PubMed: 7541200.
21. Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH et al. (2004) In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 78: 13553-13561. doi:10.1128/JVI.78.24.13553-13561.2004. PubMed: 15564466. (Pubitemid 39612755)
22. Uberla K, Stahl-Hennig C, Böttiger D, Mätz-Rensing K, Kaup FJ et al. (1995) Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 92: 8210-8214. doi:10.1073/pnas.92.18.8210. PubMed: 7545297.
23. Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S et al. (2011) Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol 85: 1067-1076. doi:10.1128/JVI.01701-10. PubMed: 21084490.
24. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K et al. (2007) Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 81: 12145-12155. doi:10.1128/JVI.01301-07. PubMed: 17855539. (Pubitemid 350085830)
25. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP et al. (2004) Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305: 528-532. doi:10.1126/science.1098632. PubMed: 15247437. (Pubitemid 38971345)
26. Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C et al. (2004) Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother 48: 3483-3490. doi:10.1128/AAC.48.9.3483-3490.2004. PubMed: 15328115. (Pubitemid 39129349)
27. Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB et al. (2003) Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 77: 4938-4949. doi:10.1128/JVI.77.8.4938-4949.2003. PubMed: 12663799. (Pubitemid 36402842)
28. Cline AN, Bess JW, Piatak M Jr., Lifson JD (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303-312. doi:10.1111/j.1600-0684.2005.00128.x. PubMed: 16128925. (Pubitemid 41179592)
29. Siliciano JD, Siliciano RF (2005) Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals; T Zhu. New York: Humana Press.
30. Chomczynski P, Mackey K (1995) Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. BioTechniques 19: 942-945. PubMed: 8747660. (Pubitemid 3021405)
31. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818. doi:10.1002/sim.4780090710. PubMed: 2218183. (Pubitemid 20343989)
32. Julias JG, Ferris AL, Boyer PL, Hughes SH (2001) Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol 75: 6537-6546. doi:10.1128/JVI.75.14.6537-6546.2001. PubMed: 11413321. (Pubitemid 32578173)
33. Koelsch KK, Liu L, Haubrich R, May S, Havlir D et al. (2008) Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 197: 411-419. doi:10.1086/525283. PubMed: 18248304. (Pubitemid 351263423)
34. Mexas AM, Graf EH, Pace MJ, Yu JJ, Papasavvas E et al. (2012) Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 26: 2295-2306. doi:10.1097/QAD. 0b013e32835a5c2f. PubMed: 23014521.
35. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517. doi:10.1038/8394. PubMed: 10229227. (Pubitemid 29220209)
36. Ledderose C, Heyn J, Limbeck E, Kreth S (2011) Selection of reliable reference genes for quantitative real-time PCR in human T cells and neutrophils. BMC Res Notes 4: 427. doi:10.1186/1756-0500-4-427. PubMed: 22011438.
37. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA et al. (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9: e1003174. PubMed: 23459007.
38. Bull M, Learn G, Genowati I, McKernan J, Hitti J et al. (2009) Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLOS ONE 4: e7122. doi:10.1371/journal.pone.0007122. PubMed: 19771165.
39. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM et al. (1994) Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 68: 7467-7481. PubMed: 7933130.
40. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP et al. (2003) Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol 77: 12336-12345. doi:10.1128/JVI.77.22.12336-12345.2003. PubMed: 14581570. (Pubitemid 37339886)
41. Poss M, Rodrigo AG, Gosink JJ, Learn GH, de Vange Panteleeff D et al. (1998) Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol 72: 8240-8251. PubMed: 9733867. (Pubitemid 28421821)
42. Blackard JT (2012) HIV compartmentalization: a review on a clinically important phenomenon. Curr HIV Res 10: 133-142. doi: 10.2174/157016212799937245. PubMed: 22329519.
43. Hendrix CW (2012) The clinical pharmacology of antiretrovirals for HIV prevention. Curr Opin HIV AIDS 7: 498-504. doi:10.1097/COH.0b013e32835847ae. PubMed: 22964888.
44. Yukl SA, Shergill AK, Ho T, Killian M, Girling V et al. (2013) The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence. J Infect Dis, 208: 1212-20. PubMed: 23852128.
45. Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J et al. (2013) Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. PLoS Pathog 9: e1003432. PubMed: 23818847.
46. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A et al. (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84: 2913-2922. doi:10.1128/JVI.02356-09. PubMed: 20032180.
47. Zink MC, Brice AK, Kelly KM, Queen SE, Gama L et al. (2010) Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral. DNA - J Infect Dis 202: 161-170. doi:10.1086/653213.
48. Clements JE, Mankowski JL, Gama L, Zink MC (2008) The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol 14: 309-317. doi: 10.1080/13550280802132832. PubMed: 18780232.
49. Hogan C, Wilkins E (2011) Neurological complications in HIV. Clin Med 11: 571-575. doi:10.7861/clinmedicine.11-6-571. PubMed: 22268312.
50. Clements JE, Gama L, Graham DR, Mankowski JL, Zink MC (2011) A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS 6: 37-42. doi:10.1097/COH.0b013e3283412413. PubMed: 21242892.
51. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L et al. (2010) Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 7: 78. doi:10.1186/1742-4690-7-78. PubMed: 20868521.
52. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA et al. (2012) Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 8: e1002506. PubMed: 22319447.
53. Lerner P, Guadalupe M, Donovan R, Hung J, Flamm J et al. (2011) The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol 85: 4772-4782. doi:10.1128/JVI.02409-10. PubMed: 21345945.
54. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106: 9403-9408. doi:10.1073/pnas.0903107106. PubMed: 19470482.
55. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM et al. (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7: ([MedlinePgn:]) PubMed: 20711481.
56. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH et al. (2011) A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 203: 960-968. doi:10.1093/infdis/jiq138. PubMed: 21402547.
57. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M et al. (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50: 912-919. doi: 10.1086/650749. PubMed: 20156060.
58. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D et al. (2013) Increase in 2-Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. J Infect Dis 208: 1436-1442. doi:10.1093/infdis/jit453. PubMed: 23975885.
59. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197: 714-720. doi:10.1086/527324. PubMed: 18260759. (Pubitemid 351364472)
60. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q et al. (2010) Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202: 1553-1561. doi:10.1086/656722. PubMed: 20939732.
61. Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 100: 4819-4824. doi:10.1073/pnas.0736332100. PubMed: 12684537. (Pubitemid 36457812)
62. Telenti A, Johnson WE (2012) Host genes important to HIV replication and evolution. Cold Spring Harb Perspect Med 2: a007203. PubMed: 22474614.